Glen Tullman, Transcarent CEO
January 8, 2025 12:23 PM ESTUpdated 03:15 PM
Deals
Health Tech

Tran­scar­ent buys health nav­i­ga­tion in­cum­bent Ac­co­lade for $621M

Ngai Yeung

Health Tech Reporter

Uni­corn start­up Tran­scar­ent has bought up a pub­licly trad­ed ri­val as it looks to ex­pand as a health nav­i­ga­tion gi­ant in one of the first …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Gene edit­ing start­up Scribe Ther­a­peu­tics lets go of staff as it preps for the clin­ic

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

Re­silience cuts 120 em­ploy­ees at a for­mer blue­bird gene ther­a­py site

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

A service from the Financial Times